<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03814759</url>
  </required_header>
  <id_info>
    <org_study_id>4-2015-0603</org_study_id>
    <nct_id>NCT03814759</nct_id>
  </id_info>
  <brief_title>Preoperative Chemoradiotherapy for Locally Advanced Resectable Gastric Adenocarcinoma</brief_title>
  <official_title>Preoperative S-1 Plus Cisplatin-based Chemoradiotherapy for Locally Advanced Resectable Gastric Adenocarcinoma : Randomized, Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastric cancer is a high incidence in Asia, and one of the leading cause of death in Korea. A
      cure rate is improving due to early diagnosis. However, the 5-year survival rate of gastric
      cancer excluding early gastric cancer is about 40 ~ 67%. Therefore, several methods for
      lowering the recurrence rate have been attempted and concurrent chemoradiotherapy can be
      considered as a method to lower the recurrence rate of gastric cancer. The purpose of this
      study is to evaluate the pathologic response rate and safety of patients who underwent
      surgery after chemoradiotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2016</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathological response rate</measure>
    <time_frame>10 week</time_frame>
    <description>to evaluate pathological response rate in locally advanced resectable gastric cancer</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Gastric Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>SP+CCRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-1 20mg/m2, bid (D1~14, D22~35) Cisplatin 30mg/m2/day (W1, 2, 4, 5) radiation 45Gy per 5 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-1 + cisplatin</intervention_name>
    <description>S-1 20mg/m2, bid (D1~14, D22~35) Cisplatin 30mg/m2/day (W1, 2, 4, 5)</description>
    <arm_group_label>SP+CCRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation</intervention_name>
    <description>radiation 45Gy per 5 weeks</description>
    <arm_group_label>SP+CCRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age â‰¥ 20 years old

          2. Histologically confirmed gastric adenocarcinoma

          3. clinical stage : resectable gastric cancer

               -  advanced confirmed (EGD)

               -  extramural infiltration&gt; 1 mm (CT)

               -  positive serosa invasion (EUS)

          4. Eastern Cooperative Oncology Group performance status 0 or 1

          5. no prior chemotherapy and radiotherapy

          6. measurable lesion or evaluable lesion according to Response Evaluation Criteria in
             Solid Tumors version 1.1 criteria

          7. Patients with adequate organ function

          8. Signed informed consent

        Exclusion Criteria:

          1. Metastasis esophageal invasion &gt; 3cm

          2. inoperable peritoneal seeding disease determined by exploratory laparotomy

          3. T4b invading the surrounding organs

          4. lymph node metastasis outside the celiac trunk Lymph node and splenic lymph node

          5. uncontrolled viral infections (HIV, HBV, HCV)

          6. Pregnant or lactating women, women of childbearing potential not employing adequate
             contraception

          7. severe hypersensitivity reactions to S-1, cisplatin

          8. Subjects with uncontrolled clinically significant cardiovascular medical history,
             uncontrolled infection or complication

          9. Other co-existing malignancies or malignancies diagnosed within the last 5 years
             except for curatively treated non-melanoma skin cancer or in situ carcinoma of the
             cervix
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hyo Song Kim</last_name>
    <phone>82-2-2228-8124</phone>
    <email>hyosong77@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyo Song Kim</last_name>
      <phone>82-2-2228-8124</phone>
      <email>hyosong77@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 23, 2019</study_first_submitted>
  <study_first_submitted_qc>January 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2019</study_first_posted>
  <last_update_submitted>January 10, 2020</last_update_submitted>
  <last_update_submitted_qc>January 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Hyo Song Kim</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

